Dong-A expands in painkiller market

Published: 2009-10-20 06:56:00

Updated: 2009-10-20 06:56:00

Boosted by robust sales of a new isopropylantipyrine (IPA)-free painkiller “Amcilon Q”, Dong-A Pharm is attempting to become a leading player in the domestic analgesic market, which has been dominated by Samjin’ Geworon, Chong Kun Dang’s Penzal and Janssen Korea’s Tylenol.

While Samjin and Cho...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK